Tonix Appoints Gary Ainsworth As Vice President During FDA Review For Fibromyalgia

Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company concentrating on marketed products and a development pipeline. The firm has recently announced the appointment of Gary Ainsworth as Vice President of Market Access, effective immediately. Mr Ainsworth brings experience in market access strategies, having held key leadership roles in major pharmaceutical companies and healthcare consultancies.

Before joining Tonix, Mr Ainsworth served as managing director and head of market access at Eversana Intouch, where he tried to maximise the company’s extensive market access services. He also founded and led Havas Gemini, the Market Access Business Unit of Havas Health & You, which specialised in developing innovative strategies for healthcare clients. 

Additionally, he held pivotal roles in the pharmaceutical sector, including Vice President of Corporate Accounts and Customer Operations at Baxter International’s Anesthesia, Critical Care, and Oncology Division and leadership positions in market access at Roche Laboratories and Sanofi’s predecessor companies. Mr. Ainsworth earned an MBA from Rockhurst University and a dual bachelor’s degree in Business Administration and Public Relations from William Jewell College.

Tonix recently announced that the FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025. The was assigned for its decision on the commercialisation of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), a non-opioid treatment for fibromyalgia. This chronic pain condition, which predominantly affects women, remains a significant unmet medical need. 

Thomas Englese, EVP Commercial of Tonix Pharmaceuticals, commented, “Gary has a significant track record of success building market access functions, developing launch-ready access and reimbursement strategies and payer-focused resources, including those for fibromyalgia and migraine treatment options. His extensive experience will be especially valuable as we work towards the potential approval and commercial launch of TNX-102 SL for managing fibromyalgia this year.”

“Joining the Tonix team presents an exciting and fulfilling opportunity to help advance a treatment for the millions of individuals with fibromyalgia. I look forward to providing additional expertise to a seasoned leadership team to bring meaningful therapeutics to patients in need,” stated Mr. Ainsworth.